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modelling of ﬁlter capacity and viral clearance by mitigating
the impact of virus spike impurities
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Endogenous and adventitious virus removal by size-
exclusion membrane ﬁltration is a critical dedicated
step in an overall viral clearance strategy employed
by biologics manufacturers as required by industry
regulators. However, the addition of impurities from
virus spike preparations used in validation studies
can signiﬁcantly reduce ﬁlter capacity, resulting in
an oversized and suboptimal virus ﬁltration step.
The hydraulic ﬁlter performance and virus retention
observed in conventional scaled-downed validation
models may not necessarily represent performance ob-
served during process development, nor be predictive
of manufacturing performance. Using ﬁlter ﬂow decay
as a relevant processing endpoint, an alternative and
more comprehensive approach to virus ﬁlter validation
has been developed to overcome the limitations
imposed by virus spike impurities. With a model
feedstream, we have demonstrated comparable virus
removal using the conventional virus spiking approach
and a complementary preconditioned virus challenge.
Similar to a currently accepted method used in the val-
idation of sterilizing-grade ﬁlters, this method entails
processing non-spiked feed to a volumetric throughput
target, followed by processing virus-spiked feed to a
ﬁnal ﬂow decay endpoint to determine viral clearance.
This comprehensive approach yields predictive virus
retention data under protein-dominant fouling condi-
tions that better model the hydraulic performance of
the manufacturing-scale virus ﬁltration operation.
Introduction
Cell lines commonly used in biotechnology manufacturing
processes, such as CHO cells (Chinese-hamster ovary
cells), have been demonstrated to produce retrovirus-like
particles. Although these particles are believed to be non-
infectious, this source of endogenous virus contamination
is of particular safety concern due to risk of activation
by superinfection [1–3]. Moreover, MMV (murine minute
virus) contamination in a large-scale biologics manufacturing
process has previously been observed and was attributed to
adventitious contamination of raw materials used in produc-
tion [4,5]. Consequently, international regulatory agencies
require biologics manufacturers to employ a comprehensive
viral clearance strategy, including characterization of cell
lines and raw materials, employing robust viral inactivation
and removal steps, and testing of process intermediates and
ﬁnal products [6–8]. Multiple orthogonal steps, including
chromatographic methods, physiochemical inactivation and
size exclusion-based ﬁltration, together yield cumulative in-
activation and removal of viruses (reviewed in [9]). Since
all processes have limitations and none can guarantee com-
plete clearance of viruses, regulatory guidance mandates
viral clearance evaluations of each effective unit operation
[8].
In the light of practical considerations of both viral
safety and cost, scaled-down process models are used for
viral clearance validations, commonly referred to as ‘spiking
studies’. Regulatory agencies require spiking studies to be
representative of the process being evaluated, including pro-
cess intermediate, buffer formulation, protein concentra-
tion, operational pressure, volumetric throughput and ﬁlter
area [6,8]. For virus ﬁltration validation, conventional spiking
studiesinvolvetheintroductionofaknownamountofavirus
preparation into the biologic feedstream and quantiﬁcation
of virus removal, LRV (log reduction value), across the
ﬁlter [10]. However, virus spikes often contain impurities,
such as proteins and nucleic acids. These contaminants are
unlikely to be present to the same extent in manufacturing,
particularly considering that the viral ﬁltration step is
generally placed after one or more chromatography steps
(reviewed in [11]). Thus current virus validation studies
deviate from truly representative scaled-down models.
Virus stock impurities can alter the hydraulic perform-
ance of the virus ﬁlters by accelerating ﬁlter fouling and
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limiting volumetric throughput, resulting in overestimation
of the ﬁlter size needed in manufacturing [12]. More con-
cerning is that virus stock impurities have been shown to el-
evatetheobservedviralclearanceinsomecases.Thisiscon-
sistent with a predominant cake fouling mechanism where a
secondary ﬁltration layer forms upstream on the membrane
and artiﬁcially aids virus retention [13]. Even in the absence
of virus spike impurities, the concentration of virus in a spike
preparation is an important consideration with respect to
ﬁlter hydraulic performance, as there exists an upper limit
of allowable virus spike concentration to maintain integrity
of the scaled-downed model of the manufacturing process
[14]. These independent studies suggest that ﬁlter hydraulic
performance, especially fouling mechanisms, needs to be
considered during virus ﬁlter validation. The possibility of
overestimating a process viral clearance claim resulting from
the use of non-representative scaled-down models presents
a signiﬁcant viral safety risk. Thus the integrity of scaled-
down models warrants greater consideration, particularly
with regard to critical processing endpoints.
Extended ﬁlter processing leads to greater variability
in virus retention across several disparate types of virus
ﬁlters, underscoring the importance of deﬁning critical
endpoints to virus ﬁltration unit operations [14]. Although
volumetric throughput is an attractive manufacturing
processing endpoint to consider in sizing a bioprocess
ﬁlter, a relationship between virus retention and ﬁlter ﬂow
decay has been clearly established for the Viresolve® NFP
(normal-ﬂow parvovirus) ﬁlter [13]. Using ﬂow decay as
the relevant processing endpoint for this virus ﬁlter, we
have developed a model system to study the utility of a
comprehensive virus validation strategy that accommodates
the accelerated ﬁlter fouling and volumetric throughput
limitations associated with virus spike impurities.
The validation method described here is similar to
an accepted and widely used technique in the validation
of sterile ﬁlters where the drug product is toxic to the
challenge organism, Brevundimonas diminuta [15,16]. Similar
to drug toxicity to test micro-organisms, instances of
spike impurities compromising the integrity of scaled-down
virus ﬁlter validation models represent a fundamental
limitation in virus spiking implementation. Following the
example of the alternative sterile ﬁltration validation
strategy, preconditioned challenging of virus ﬁlters was
evaluated as a complementary validation strategy to the
conventional spiking methodology. The method involves
running non-spiked feed material to a target volume,
followed by addition of virus and processing of spiked feed
to a ﬁnal ﬂow decay to determine viral clearance. As it is
complementary, this approach should always be employed
in conjunction with the conventional spiking method in
which virus-spiked feed is introduced from the beginning of
ﬁltration.
In evaluating this comprehensive strategy, we deﬁned
target preconditioning volumes in terms of ﬁlter ﬂow
decay, and we observed comparable virus retention
between the conventional and complementary approach
within a deﬁned window of operability. Deviations from
expected performance were consistent with changes in
ﬁlter fouling, either as a function of virus spike impurities
or extent of preconditioning. Using ﬂow decay as a relevant
process endpoint, virus retention, LRV, should always
be determined using the conventional spiking approach.
When used well within established limits, preconditioned
challenging represents a strategy to bridge an established
virus retention endpoint to ﬁlter hydraulic performance
that is more relevant to process development and thus
more predictive of the manufacturing-scale process.
Materials and methods
Model protein
BSA(Millipore,Billerica,MA,U.S.A.)wasdilutedtoﬁnalcon-
centrations of 1.0or 3.2 g/l in Difco FA buffer (pH 7.2; Fisher
Scientiﬁc, Pittsburgh, PA, U.S.A.) for use as a model protein
in spiking studies. BSA was spiked with appropriate virus
stock and/or mock MMV stock, as described in the Figures,
and ﬁltered through a 0.22-μm-pore-size ﬁlter (Millipore
Express® Plus membrane; Millipore) before virus ﬁltration.
Viruses and assays
Bacteriophage  X174 was purchased from Promega
(Madison, WI, U.S.A.) and assayed as previously described
[13]. High- and low-titre stocks of MMV (VR-1346; A.T.C.C.,
Manassas, VA, U.S.A.), as well as mock virus (clariﬁed non-
infected cell culture lysate) spikes, were prepared and
viruses were assayed as previously described [13].
High-titre MMV stocks were produced by infecting
50–70% conﬂuent T150 cell culture ﬂasks of 324K cells
(obtainedfromProfessorP.Tattersall,DepartmentsofLabo-
ratory Medicine and Genetics, Yale University School of
Medicine, New Haven, CT, U.S.A.) at an MOI (multiplicity
of infection) of 0.001. Infected cells were grown in 30 ml of
1% fetal bovine serum containing high-glucose Dulbecco’s
modiﬁed Eagle’s medium at 37◦Ca n d5%C O 2 for 5–7 days
or until 50–70% CPE (cytopathic effect) was observed.
During harvest, 20 ml of culture media was discarded from
each T150 ﬂask. The remaining intact cells were collected by
scraping them into the remaining 10 ml of medium. The cell
suspension was centrifuged at 300 g for 5 min. The super-
natant was discarded and the cell pellet was washed with
1 ml of TE buffer (10 mM Tris and 1 mM EDTA, pH 8.7)
per T150 ﬂask harvested by re-centrifuging at 300 g for
5 min. Three freeze–thaw cycles were used to lyse the
cells, and the resulting lysate was clariﬁed by centrifugation
(18000 g for 20 min). Supernatant from clariﬁcation was
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then ultracentrifuged (25 000 rev./min, sw-28 rotor, for
18 h), the virus pellet was resuspended in one-quarter of
the starting supernatant volume of TE buffer, and stored at
–80◦C until ready for use in spiking studies.
Low-titre, ‘crude’ MMV stocks were prepared as
described for the high-titre MMV stock method with the
following exceptions. The culture was harvested by three
cycles of freeze-thawing the T150 ﬂasks containing infected
cells and 30 ml of culture media. The lysate was centrifuged
(300 g for 5 min) to remove cell debris and the supernatant
was 0.22-μm-pore-size-preﬁltered and stored at − 80◦C
until ready for use in spiking studies.
Mock MMV stocks were prepared by a method
identical with the low-titre MMV stock method with the
exception that the cells were mock-infected with virus-free
media. Harvest was performed on day 5 because no CPE
was observed or expected.
Filtration experiments
All virus ﬁltration studies were performed using Viresolve®
NFP membrane in Optiscale®-25 devices (Millipore).
Hydraulic performance was monitored gravimetrically as
a function of volume processed at 1 min increments using
gram balances (Mettler-Toledo, Columbus, OH, U.S.A.)
and data acquisition software (DasyLab 7.0; National
Instruments, Austin, TX, U.S.A.). The densities of aqueous
wetting buffers and feed materials were assumed to be
1.0 g/ml. Flow rates (ml/min), ﬂow decay (ﬂow rate relative
to initial buffer ﬂow rate) and volumetric throughput (l/m
2,
based on a membrane area of 3.5 cm
2) were calculated
for all experiments. Virus ﬁlters were pre-wetted using
FA buffer at a constant pressure of 414 kPa (60 lbf/in
2)f o r
5 min, followed by 207 kPa (30 lbf/in
2) for another 5 min,
for a total wetting time of 10 min. The initial buffer ﬂow
rate (ml/min) was determined between 9 and 10 min of the
wetting step. In all cases, percentage ﬂow decay was based
on the initial buffer ﬂow rate.
Conventional spiking experiments.  X174 and mock MMV
stock were added to feeds as described in the Figures,
followed by ﬁltration through a 0.22-μm-pore-size ﬁlter.
Spiked feed was processed through the virus ﬁlters to
the 75% ﬂow decay endpoint. With the exception of the
experiments shown in Figure 1, samples were collected
from the bulk pool ﬁltrates at appropriate sample points as
described in the Figures. The samples collected in Figure 1
were2 ml‘instantaneous’or‘grab’samplescollecteddirectly
into the sample tubes at the desired sample points.
Preconditionedchallengeexperiments. Non-spikedandspiked
feed materials were 0.22-μm-pore-size-ﬁltered and loaded
into parallel pressure vessels connected to virus ﬁlters using
three-way male lock stopcock valves (Cole-Parmer). The
non-spiked feed was processed ﬁrst to the desired ﬂow
Figure 1 Virus retention is dependent on ﬁlter ﬂow decay state rather than
volumetric throughput
Bacteriophage X174 was added to three concentrations of a therapeutic
protein and ﬁltered. Instantaneous/grab ﬁltrate samples were collected as the
ﬁltration progressed and samples were assayed using a standard plaque assay.
Bacteriophage retention (LRV) was calculated by comparing ﬁltrate titres with
feed titres. LRV was plotted against (A) volumetric throughput (l/m
2)a n d
(B) ﬂow decay (%) relative to initial buffer ﬂow rate.
decay as described in the Figures. The three-way valve
was then used to switch to spiked feed without pressure
interruption. The spiked feed was then processed to the
75% ﬂow decay endpoint. Filtrates from the non-spiked
and spiked parts of the process were collected in separate
collection vessels. Final samples were collected from the
bulk pool of the spiked ﬁltrations only.
Results
The goals of optimizing small-virus ﬁltration in downstream
bioprocessing are to maximize ﬁlter capacity as a function
of protein mass throughput, establish LRV for relevant and
model viruses, incorporate safety margins and establish
process controls [11]. Although not applicable to all virus
ﬁlters, a clear relationship between virus retention and
ﬁlter ﬂow decay has been established for Viresolve® NFP
ﬁlters [13,17]. Bacteriophage provide a relevant model
system by which to understand the relationship between
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ﬁlter-retentivepropertiesandprocessconditions[13,14,17–
19]. The relationship between LRV and ﬂow decay is
illustrated in Figure 1, where increasing concentrations of a
therapeutic protein were spiked with  X174 and processed
through Viresolve® NFP ﬁlters.
Volumetric throughput decreased with increasing pro-
tein concentrations (Figure 1A). However, the relationship
between LRV decline and ﬂow decay is apparent through the
collapsing of curves irrespective of protein concentration
(Figure 1B), a ﬁnding consistent with previous observations
[17]. Higher virus retention before a 75% ﬂow decay thres-
hold underscores the value of monitoring ﬂow decay during
process development, manufacturing and, particularly, in
scaled-down small-virus ﬁlter validation models. The
relationship between ﬂow decay and LRV is consistent with
a complete pore-blocking model, where fouling occurs ﬁrst
at smaller, virus-retentive pores, leading to an increased
proportion of ﬂow through larger, non-retentive pores over
time [13].
Virus spike impurities have a signiﬁcant adverse effect
on virus ﬁlter hydraulic performance [12]. Using different
puriﬁcation strategies, virus spike preparations comprise
disparate levels of contaminating protein and, to a lesser
extent, nucleic acid. Using low-speed centrifugation alone to
generate ‘crude’ preparations, MMV spikes typically contain
upwards of 15 pg of protein per TCID50 (median tissue-
culture infective dose; that amount of a pathogenic agent
that will produce pathological change in 50% of cell cultures)
and less than 10 fg of nucleic acid per TCID50 (results not
shown). In contrast, pelleting virus by ultracentrifugation
yields MMV preparations of high titre and high purity, which
typically exhibit 100-fold less contaminating protein and
5-fold less nucleic acid than crude spikes. These spikes
typically contain less than 10 fg per TCID50 protein and less
than 2 fg per TCID50 nucleic acid (results not shown).
As shown in Figure 2(A), the BSA ﬂux versus
throughput performance of the virus ﬁlter is clearly a
function of virus spike purity. Spiking protein with a relatively
crude MMV preparation accelerated ﬂow decay and limited
volumetric throughput. In contrast, spiking with a high-
titre,high-purityMMVpreparationdidnotnoticeablychange
ﬁlter hydraulic performance as compared with protein alone
(Figure 2A). Similarly, spiking with a high-purity bacterio-
phage  X174 had negligible impact on ﬁlter hydraulic
performance as compared with protein alone (Figure 2B),
whereas addition of a mock preparation of crude MMV to
the  X174 and protein accelerated ﬁlter ﬂow decay and
limited volumetric capacity. Many mammalian viruses have
been observed to have particle-to-infectivity ratios of the
order of 100–1000-fold and higher [20]. Thus spiking a virus
ﬁlter with a mammalian virus preparation may skew both
hydraulic and LRV performance to a virus-governed fouling
proﬁle, which would not be representative of manufacturing.
Figure 2 Virus spike impurities accelerate membrane fouling
Filtration hydraulic performance was compared for feeds with and without
spike impurities. Non-spiked 1.0 g/l BSA was also processed. All ﬁltrations were
run under a constant pressure of 207 kPa (30 lbf/in
2). Flux was plotted against
volumetric throughput. Five devices were tested simultaneously per condition
andtheydemonstratedsimilartrends;representativeresultsareshownforeach
condition. (A) 1.0 g/l BSA was spiked with either puriﬁed or crude MMV stocks
to a ﬁnal concentration of 2.5×10
6 TCID50/ml and ﬁltered. (B)1 . 0g / lB S A
was spiked to a ﬁnal concentration of 2.0×10
8 pfu (plaque-forming units)/ml
with either X174 or X174 plus 0.5% mock MMV stock, and ﬁltered.
The similarity in hydraulic impact between the crude
virus preparation and mock virus preparations indicates
that virus stock impurities have a more pronounced effect
on virus ﬁltration hydraulic performance than virus particle-
to-infectivity ratios (Figure 2). Although not standard prac-
tice in our laboratory, transmission electron microscopy has
been used to assess particle-to-infectivity ratio of MMV. On
the basis of a sample physical characterization, the ratio of
virus particle to TCID50 unit was calculated to be approx.
3000:1 (results not shown). Thus it must be noted that,
in the absence of routine physical virus characterization
methods, a similar particle-to-infectivity ratio can only
be assumed for the MMV stocks employed in these
studies. Nonetheless, the similarity in hydraulic impact-
between a crude virus stock and a mock preparation of
the same demonstrates the utility of using the latter, plus
bacteriophage, to represent a worst-case model of virus
spike purity. A crude spike of a partially retained virus is
likely to promote premature ﬁlter fouling and yield
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Figure 3 Virus stock impurities decrease volumetric throughput and
artiﬁcially elevate virus retention in a concentration-dependent manner
X174 was added to 1.0 g/L BSA to a ﬁnal concentration of 5.0×10
8 pfu/ml.
Three feed solutions were prepared from this stock solution containing no
mock MMV and ﬁnal concentrations of 0.5 and 1% mock MMV. The feeds
were ﬁltered to 75% ﬂow decay. Final pooled samples were assayed for
infectivity using a standard plaque assay. LRV75 was calculated based on the
concentration of virus in the ﬁltrates relative to the feed concentrations. Five
devices were tested per condition. All conditions were tested concurrently
(two-tailed, unpaired Student t test; P=0.0009).
potentially elevated LRVs and thus represents a worst-case
scenario for both ﬁlter sizing and viral safety [12]. In such
a scenario, ﬁlters would likely be oversized, which presents
economic challenges to implementation and scale-up. More
concerning is that from a viral safety perspective, the use
of crude virus spikes in clearance studies may lead to
overestimation of the viral clearance of the ﬁlter employed.
A ss h o w ni nF i g u r e3 ,b a c t e r i o p h a g e X174-spiked
BSA exhibited reduced throughputs with increasing concen-
trations of mock MMV spike. In addition, virus retention was
signiﬁcantly increasedattheextremeofmockconcentration
tested (two-tailed, unpaired Student t test; P=0.0009). As
shown, virus spike impurities accelerated ﬂow decay, limited
ﬁlter capacity andartiﬁcially elevatedretentive performance.
Thus virus ﬁlter process development and validation study
designs should always consider the adverse impact of virus
spike impurities in deﬁning both critical process parameters
and relevant operational endpoints, especially with respect
to mechanisms of virus ﬁlter fouling and retention. The
same considerations should also factor in when considering
alternatives to conventional spiking evaluations.
The complementary, preconditioned challenge ap-
proach to virus ﬁlter validation involves ﬁltering the non-
spiked process intermediate to a volumetric throughput
within well-designed safety margins, followed by ﬁltering
virus-spiked intermediate to the desired process endpoint
(Figure 4). Quite simply, preconditioned challenging com-
plements the conventional spiking approach; it bridges
virus retention under hydraulic performance conditions
predictive of manufacturing-scale processes with virus
retention predicted when spike impurities compromise the
integrity of the scaled-down model. The relationship of
Figure 4 Preconditioned challenging complements the conventional virus
spiking method
LRV is established using the conventional spiking method, a one-step ﬁltration
during which the virus ﬁlter is challenged with virus containing feed material
from the onset of the ﬁltration. Throughput volume is established using the
preconditioned challenge, a two-step process in which the biologic (no virus
added) is ﬁrst ﬁltered to a target throughput. Spiked feed is then introduced
on to the same ﬁlter and processed to a ﬁnal ﬂow decay endpoint (e.g. V75).
Viresolve® NFP ﬁlter virus retention to ﬂow decay dictates
that volumetric limits of a preconditioned challenge are
understood in terms of the percentage ﬂow decay.
Following a complete pore-blocking model of virus
retention for Viresolve® NFP ﬁlters, it is expected that
fouling will lead to a shift in proportionate ﬂow distribution
towards larger, non-retentive pores, leading to increased
virus passage as a function of ﬂow decay [13]. However,
increased viral loads accelerate ﬁlter fouling and often
artiﬁcially skew LRV upward [14]. Thus, to establish safety
limits well within the highly retentive performance range
(Figure 1B), we evaluated virus retention at a 75% ﬂow
decay endpoint (V75) after spiking preconditioned ﬁlters
with virus (Figure 4). In all cases, the preconditioned
challenge was run alongside a conventional spiking study
using the same lot of model BSA feedstream as a control
(Figure 4). In the conventional spiking controls, BSA
was spiked with a mixture of  X174 and a mock MMV
preparation. For the preconditioned challenges, non-spiked
BSA was run to deﬁned points of ﬂow decay, at which point
the ﬁlters were challenged with bacteriophage/mock-spiked
BSA, followed by continued ﬁltration to the V75 endpoint.
Initial studies sought to challenge ﬁlters with equal virus
particle loads. However, there appeared to be no impact
of virus concentration or total virus particle load on pooled
LRV at the V75 ﬂow decay endpoint within the  X174 con-
centrations tested (Table 1). Throughput volumes obtained
in either the conventional spiking or the preconditioned
challenge were likewise unaffected by total viral loads within
the range tested (Table 1). However, throughput volumes
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Table 1 Total  X174 viral loads between 10
8 and 10
10 pfu do not affect volumes processed or virus retention
Abbreviation: NA, not applicable (non-spiked feed was not processed during conventional spiking).
Spiking Virus spike Average non-spiked Average spiked Average total Total viral X174 pool
method
a titre (pfu/ml) volume processed (ml) volume processed (ml) volume processed (ml) load (pfu) LRV75
Conventional
A3 . 9 ×10
7 NA 39.6 39.6 1.5×10
9 5.1+ −0.1
B4 . 0 ×10
8 NA 42.3 42.3 1.7×10
10 5.5+ −0.1
V50 spike
A
b 3.9×10
7 84.2 17.9 102.1 6.9×10
8 5.3+ −0.4
B
b 4.0×10
8 86.2 19.4 105.6 7.6×10
9 5.5+ −0.2
a3.9×10
7 and 4.0×10
8 pfu/ml X174 were spiked into 1.0 g/l BSA and processed through Viresolve® ﬁlters to a 75% ﬂow decay endpoint; pooled samples
were collected from bulk ﬁltrates at the end of the runs and assayed for infectivity; ﬁve devices were tested per condition.
bPreconditioned challenging was evaluated at the same spike concentrations; however, less volume of spike was processed than expected during subsequent
spiking phases, so target viral loads were not achieved.
obtained between the two approaches, conventional spiking
versus the preconditioned challenge, yielded very different
results at V75 (Table 1). In contrast, similar LRV results were
obtained for conventional spiking approach and virus spiking
after preconditioning to 50% ﬂow decay (Table 1). These
results provide supportive evidence that the ﬁlter-retentive
properties are similar with protein preconditioning to 50%
ﬂow decay.
Filter preconditioning provides a complementary virus
spiking strategy to address hydraulic limitations often en-
countered in conventional scaled-down models, particularly
forViresolve® NFPﬁlters.However,theapproachdoeshave
its limitations, which, as expected, are related to ﬂow decay
(Figure 5). While preconditioning to 30% ﬂow decay had no
observable impact on LRV as compared with conventional
spiking, preconditioning to 60% ﬂow decay resulted in an
elevated ﬁnal pooled LRV in the case of low-concentration
BSA (Figure 5A). The observed trend towards higher LRVs
with increased protein preconditioning is counterintuitive to
the complete pore-blocking model, which predicts that LRV
would decrease under such conditions.
That extended preconditioning results in an elevated
LRV is probably indicative of immediate or premature
ﬁlter caking upon addition of high concentrations of virus
and/or foulants. However, ﬁlter caking is not sufﬁcient to
explain the elevated LRV, since it was also dependent on
the ﬁltered protein concentration (Figure 5B). At a higher
BSA concentration, an elevated LRV was not observed after
preconditioning to 60% ﬂow decay condition. Other pheno-
mena may explain the increased LRV when preconditioning
to 60% ﬂow decay for the lower concentration feed; further
study is needed. In both experiments, preconditioning
resulted in improved volumetric throughputs relative to the
conventional method, although the gain in throughput was
negligible for the V30 challenge.
It is clear that virus spike impurities have the
potential to artiﬁcially elevate virus retention (Figure 3),
consistent with ﬁlter caking. Similarly, mock MMV concen-
tration was determined to be a signiﬁcant factor for LRV in
a designed experiment that evaluated the preconditioned
challenge endpoints and mock preparation concentrations
(P<0.001; results not shown). Moreover, mock prepar-
ation demonstrated an interaction with the extent of
preconditioned challenging, such that LRV was elevated by a
combination of high mock concentration and precon-
ditioning to 60% ﬂow decay (results not shown).
Collectively, these results indicate that the inconsistent LRV
after preconditioning to 60% ﬂow decay is likely a function
of cake fouling by the mock MMV preparation, or more
generally of virus spike impurities. Given the inconsistent
LRV data observed when spiking at 60% ﬂow decay, we
sought to establish the limits of preconditioned challenging
inside the 60% ﬂow decay window of our worst-case model.
To explore the window of operability of the
precondition challenge approach with low-concentration
feed, experiments were performed to compare the
conventional spiking approach to the preconditioning to 50
and 60% ﬂow decay, followed by virus challenges (Figure 6).
Preconditioning to 50% ﬂow decay resulted in dramatic
volumetric throughput gains, whereas the LRVs remained
comparable with those obtained using the conventional
approach. Preconditioning to 60% ﬂow decay resulted in
elevated LRVs, as expected, but minimal throughput gains
relative to a V50 challenge. Based on our model system,
which was designed to represent a worst-case scenario
with respect to virus spike impurities, preconditioning to
50% ﬂow decay represents a safe operating window within
which to design a comprehensive virus validation study.
Discussion
Virus spike impurities represent a frequently encountered
limitation to the implementation of scaled-down virus ﬁlter
C   2009 Portland Press Ltd
© 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.
© 2009 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commerical use, distribution and reproduction in any medium, provided the original work is properly cited.Comprehensive virus ﬁlter validation strategy 299
Figure 5 Virus spiking after ﬁlter preconditioning to 60% ﬂow decay
elevates LRV in a BSA concentration-dependent manner
Spiked feeds were prepared to ﬁnal mock MMV and X174 ﬁnal
concentrations of 0.5% and 2×10
8 pfu/ml respectively. (A)N o n - s p i k e dB S A
at 1.0 g/l was processed to either 30 or 60% ﬂow decay (V30 or V60),
followed by spiked feed to a 75% ﬂow decay endpoint. Conventional spiking
was also run in parallel (two-tailed, unpaired Student t test; P=0.0012).
(B) Non-spiked BSA at 3.2 g/l was processed to either 30 or 60% ﬂow
decay (V30 or V60) followed by spiked feed to a 75% ﬂow decay endpoint.
Conventional spiking was also run in parallel. In both (A)a n d( B), LRV75 was
determined by comparing total virus loaded on to the ﬁlters with total virus in
the ﬁltrates. Hold-up volume of the devices was factored into the calculation
for total virus loaded. All conditions were run concurrently with ﬁve devices
tested per condition.
validation models. The impurities in virus spike preparations
have been demonstrated to skew small-virus LRV upwards
as a consequence of ﬁlter fouling mechanisms that are
not representative of the manufacturing process being
validated (Figures 3, 5 and 6; [12]). In these and similar
situations, alternative small-virus validation approaches are
warranted, but such risk-based approaches need to err
on the conservative side of viral safety. An understanding
of the virus retention mechanisms of a small-virus ﬁlter is
clearly advantageous in establishing a more comprehensive
virus validation strategy. For Viresolve® NFP ﬁlters, virus
retention is primarily a function of ﬁlter ﬂow decay, but
the relationship changes predictably in the presence of non-
representative ﬁlter foulants [12,13]. An understanding of
the Viresolve® NFP ﬁlter’s virus-retention mechanisms
enabledthedevelopmentandevaluationofacomplementary
Figure 6 Filter preconditioning to 50% ﬂow decay represents a safety limit
to the complementary approach to virus ﬁlter validation
BSA (1.0 g/l) was prepared for use as a model protein. An aliquot of 1.0 g/l BSA
was spiked with a simulated virus stock to give mock MMV and X174
ﬁnal concentrations of 0.5% and 2×10
8 pfu/ml respectively. The remaining
non-spiked BSA was processed to 50 or 60% ﬂow decay. Spiked feed was
introduced upon reaching these ﬂow decay points and processed out to 75%
ﬂowdecay.Spikedcontrols(conventionalmethod)wereruninparallelwiththe
preconditioned challenges. LRV75 was calculated based on the concentration of
virus in the ﬁltrates from only the spiked phase of the experiments relative to
the feed concentrations. Hold-up volume of the devices was factored into the
calculation for total virus loaded. All conditions were run concurrently with ﬁve
devices tested per condition (two-tailed, unpaired Student t test; P=0.0032).
preconditioned virus challenge to bridge volumetric ﬁlter
throughput to the representative viral clearance endpoint.
Our evaluation of preconditioned challenging used
 X174 as a model virus because bacteriophage provide
a relevant experimental system by which to understand
the relationship between ﬁlter-retentive properties and
process conditions [13,14,17–19]. The advantages of using
bacteriophagearethattheycanbeproducedathightitreand
high purity, and with low particle-to-infectivity ratios, such
that modest bacteriophage spikes have little impact on ﬁlter
hydraulic and/or retentive performance. Thus modelling
of small-virus ﬁltration is possible under fouling conditions
dominated by the process intermediate rather than an
inordinate viral load and/or virus spike impurities. However,
at higher spike titres, bacteriophage can alter virus ﬁlter
hydraulic performance and LRV, consistent with changes
in predominant fouling mechanisms from protein-governed
fouling to a more virus-governed mechanism of fouling [14].
Although we used BSA and a bacteriophage in our
model system, the approach can be extended to other pro-
teins and viruses. By example, the feasibility of the precondi-
tioned challenge using a therapeutic protein and mammalian
viruses has recently been published in [21]. The implement-
ation of a comprehensive small-virus validation study, which
includes both a conventional spiking study and the precondi-
tioned challenge, is applicable to situations where virus spike
impurities limit ﬁlter throughputs, as demonstrated herein.
However, since preconditioned challenging represents a
more conservative approach to small-virus ﬁlter validation,
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it could be applied more broadly. In cases where high-mass
throughputs are only obtained after using depth preﬁltration
[22], decoupling the preﬁlter from the virus ﬁlter to accom-
modate spiking often results in diminished throughput gains
(J. J. Parrella and P. W. Genest, unpublished work). Filter
preconditioning, then, represents a useful approach towards
bridging in-line preﬁlter-virus ﬁlter volumetric throughput
with LRV at a ﬂow decay endpoint. Similarly, the comple-
mentary preconditioning approach could be used in cases
where cytotoxicity and/or viral interference by a therapeutic
protein or buffer dictate substantial viral dilution in assaying
titre. Dramatically increasing virus spike concentrations in
these cases, designed to compensate for necessary dilutions,
often causes premature ﬁlter fouling and limits volumetric
throughput. Here again, limitations can be overcome by
including a complementary preconditioned challenge to the
conventional small-virus ﬁlter validation study.
The comprehensive virus validation strategy de-
scribed is straightforward for Viresolve® NFP ﬁlters, as
demonstrated in our evaluation. As outlined in Figure 4,
LRV is established at a ﬂow decay endpoint using the
conventional spiking approach, whereas ﬁlter throughput
is established using the preconditioned challenge. Using
the conventional small-virus ﬁlter validation, virus is spiked
into the feed material and processed through ﬁlters. LRV
is determined based on feed and ﬁltrate concentrations at
a predeﬁned ﬂow decay endpoint. Then, for the comple-
mentary approach, non-spiked process intermediate
is ﬁltered until a predeﬁned volumetric throughput target is
reached, which cannot exceed 50% ﬂow decay. Filtration of
process intermediate is stopped and virus-spiked process
intermediate is ﬁltered to the desired process endpoint.
Although primarily for reference, it would be prudent to
evaluate the LRV of the preconditioned challenge in order
to assure that it does not differ appreciably from the value
established by conventional spiking.
Since the approach is predicated on a relationship
between LRV and ﬂow decay, implementation of a comple-
mentary preconditioned challenge may currently only have
utility for Viresolve® NFP ﬁlters. It is possible, however,
that additional virus ﬁlters may become available that
exhibit a similar, predictable relationship between virus
retention and ﬁlter fouling. In any and all cases that
preconditioned virus challenging be considered, it should
always be performed alongside a conventional validation
study to better ensure viral safety. However, addition of
a complementary preconditioned challenge is only one
alternative strategy to be considered when implementation
of scaled-down virus validation models is compromised by
non-representative conditions, such as the hydraulic impact
observed with virus spike impurities.
There are other possible alternatives that one could
consider in light of their technical merits, the implemen-
tation of which would likely require discussions with
regulatory agencies. Although higher purity virus spikes
have been shown to facilitate improved hydraulic ﬁlter
performance [12], it is unclear how tractable industry-wide
adoption of different virus spike preparation methods would
be. Noteworthy, however, is that the Parenteral Drug Asso-
ciation hasbeguntoaddress industry-wide consensusonthe
importance of virus spike purity and is drafting a points-to-
consider document on the subject [23]. Irrespective of this,
higher-purity virus spikes are unlikely to overcome the need
for spiking alternatives in the cases of preﬁlter decoupling
or increased percentage spikes required to overcome cyto-
toxicity and/or viral interference by a process intermediate
or buffer. Other potential alternative virus spiking strategies
include moving towards MMV alone as the worst-case chal-
lenge virus for ﬁlter validation. MMV is a relevant concern
[4,5] and it represents the smallest virus likely to contamin-
ate a biotechnological process. Just as B. diminuta is used as
a standard challenge organism to validate sterile ﬁlters (re-
viewed in [15]), so too could small-virus ﬁlters be validated
simply using MMV. The strength of this approach is that it
leverages the size-exclusion mechanism of small-virus ﬁlters,
and allows one to claim retention of larger viruses simply by
analogy to the smallest virus challenged. However, as MMV
is sometimes only partially retained in the ﬁlter, analogous
claims based on size may fall short of desired claims for lar-
ger, fully retained viruses, such as endogenous retroviruses.
Inthesecases,largevirusclearancecouldbevalidatedusinga
bacteriophage as a surrogate virus. In all cases, risk-based al-
ternatives to conventional validation studies should consider
the mechanism of virus ﬁlter retention, the appropriateness
of process endpoints and the integrity of the scaled-down
model with respect to the manufacturing process.
The trends in the biotech industry are moving towards
higherfeedtitres,fewerdownstreamprocessingsteps,more
ﬂexible manufacturing and reduced costs of goods. Higher
feed titres will likely drive the need for higher protein
mass capacity ﬁlters throughout downstream processing,
driving protein aggregation and an increased use of preﬁlters
upstream of small-virus ﬁlters. Currently, no strategy
exists to overcome the hydraulic limitations imposed by
preﬁlter decoupling required for virus spiking validation
studies. Fewer downstream processing steps will likely
increase the viral clearance burden for dedicated removal
steps, such as the small-virus ﬁlter. Here again, hydraulic
limitations imparted by the introduction of virus spike
impurities will likely continue to compromise the integrity of
scaled-down small-virus ﬁlter validation models. To achieve
greater manufacturing ﬂexibility, parts of the industry
are moving towards manufacturing templates, particularly
useful for processing highly related therapeutic proteins,
such as monoclonal antibodies. Moreover, templated
approaches seek to minimize process development time and
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expense, so the path forward will become unclear when
protein-speciﬁc, non-representative scaled-down models
are encountered. Most importantly, increased consumer
and government pressures mandate decreasing the costs
of manufactured pharmaceuticals, which will likely be
realized with the continued emergence of ofﬁcially approved
new versions of innovator biopharmaceutical products
following patent expiry (biosimilars). Although the need
to consider alternative small-virus ﬁlter spiking strategies
may be case-by-case today, it seems highly likely that virus
spiking alternatives will require increasing discussion as the
biotech industry continues its current progress towards
more ﬂexible and cost-effective manufacturing. Regulatory
standards for viral clearance validations have not been
updated since their publication 10 years ago [6–8], nor
is it clear whether updates are necessary. As necessary,
discussions with regulatory agencies are recommended
to understand the range of acceptable strategies available
in validating size exclusion-based ﬁlters, particularly
Viresolve® NFP ﬁlters, where virus retention mechanisms
and critical process endpoints are well understood.
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